ABSTRACT Interleukin-2 (IL-2) is one of the key cytokines with pleiotropic effects on immune
system. It has been approved for the treatment of metastatic renal cell carcinoma and …

Lung cancer is a complex disease composed of diverse histological and molecular types
with clinical relevance. The advent of large-scale molecular profiling has been helpful to …

Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …

Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

ABSTRACT Background Lung adenocarcinomas (LUADs) lead to the majority of deaths
attributable to lung cancer. We performed whole-exome sequencing (WES) and immune …

New insight on the interaction between the immune system and tumor has identified the
programmed death-1/programmed death-1 ligand pathway to be a key player in evading …

IRE1α-XBP1 signaling is emerging as a central orchestrator of malignant progression and
immunosuppression in various cancer types. Employing a computational XBP1s detection …

Introduction To depict the genomic landscape of Chinese early-stage lung squamous cell
carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 …

Simple Summary Recently, immunotherapy has presented new opportunities for clinical
development in the treatment of non-small cell lung cancer (NSCLC). Although effective in …

The tumor microenvironment (TME) represents a milieu that enables tumor cells to acquire
the hallmarks of cancer. The TME is heterogeneous in composition and consists of cellular …